Solid state characterization of commercial crystalline and amorphous atorvastatin calcium samples

AAPS PharmSciTech

Volumn 11, Issue 2, 2010, Pages 598-609

  Shete, Ganesh ^a   Puri, Vibha ^a   Kumar, Lokesh ^a   Bansal, Arvind K ^a  

^a NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

Author keywords

Atorvastatin calcium; Physical characterization; Thermal analysis; X ray powder diffraction

Indexed keywords

ATORVASTATIN; HEPTANOIC ACID DERIVATIVE; HYPOCHOLESTEROLEMIC AGENT; POWDER; PYRROLE DERIVATIVE;

ARTICLE; CONTACT ANGLE; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DISSOLUTION; DRUG DOSAGE FORM; PRIORITY JOURNAL; SCANNING ELECTRON MICROSCOPY; SOLID STATE; THERMAL ANALYSIS; THERMOGRAVIMETRY; TITRIMETRY; WETTABILITY; X RAY POWDER DIFFRACTION; CHEMISTRY; CONFORMATION; CRYSTALLIZATION; DRUG SCREENING; DRUG STABILITY; POWDER; SOLUBILITY;

ANTICHOLESTEREMIC AGENTS; CRYSTALLIZATION; DRUG EVALUATION, PRECLINICAL; DRUG STABILITY; HEPTANOIC ACIDS; MOLECULAR CONFORMATION; POWDERS; PYRROLES; SOLUBILITY;

EID: 77954818700     PISSN: None     EISSN: 15309932     Source Type: Journal    
DOI: 10.1208/s12249-010-9419-7     Document Type: Article

References (28)

1. Grant D J W. Theory and origin of polymorphism. In: Brittain HG, editor. Polymorphism in pharmaceutical solids. New York: Marcel Dekker; 1999. p. 1-33.
2. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Guidance for Industry ANDAs: Pharmaceutical Solid Polymorphism; 2007; Rockville, MD.
3. Aaltonen J, Allesø M, Mirza S, Koradia V, Gordon KC, Rantanen J. Solid form screening-a review. Eur J Pharm Biopharm. 2009;71:23-37.
4. Brittain HG, Bogdanowich SJ, Bugay DE, De Vincentis J, Lewen G, Newman AW. Physical characterization of pharmaceutical solids. Pharm Res. 1991;8:963-73.
5. Agrawal S, Ashokraj Y, Bharatam PV, Pillai O, Panchagnula R. Solid-state characterization of rifampicin samples and its biopharmaceutic relevance. Eur J Pharm Sci. 2004;22:127-44.
6. Carini JP, Pavei C, Silva A P C, Machado G, Mexias AS, Pereira VP et al. Solid state evaluation of some thalidomide raw materials. Int J Pharm. 2009;372:17-23.
7. Byrn S, Pfeiffer R, Ganey M, Hoiberg C, Poochikian G. Pharmaceutical solids: a strategic approach to regulatory considerations. Pharm Res. 1995;12:945-54.
8. Bernstein J. Polymorphism and patents from a chemist's point of view. In: Hilfiker R, editor. Polymorphism in the Pharmaceutical Industry. 1st ed. Weinheim: Wiley-VCH; 2006. p. 365-84.
9. Gardner CR, Walsh CT, Almarsson Ö. Drugs as materials: valuing physical form in drug discovery. Nat Rev. 2004;3:926-34.
10. Lipitor. Package Insert, Pfizer Ireland Pharmaceuticals, Dublin, Ireland. Parke Davis, Division of Pfizer Inc, New York; 2009.
11. Lau YY, Okochi H, Huang Y, Benet LZ. Pharmacokinetics of atorvastatin and its hydroxy metabolites in rats and the effects of concomitant rifampicin single doses: relevance of first-pass effect from hepatic uptake transporters, and intestinal and hepatic metabolism. Drug Metab Dispos. 2006;34:1175-81.
12. Kasim NA, Whitehouse M, Ramachandran C, Bermejo M, Lennerna H, Hussain AS et al. Molecular properties of WHO essential drugs and provisional biopharmaceutical classification. Mol Pharmaceutics. 2004;1:85-96.
13. Yu LX. An integrated model for determining causes of poor oral drug absorption. Pharm Res. 1999;16:1883-7.
14. Sonje VM, Kumar L, Meena CL, Kohli G, Puri V, Jain R, et al. Atorvastatin calcium. Profiles of drug substances, excipients and related methodology: Elsevier Inc.; 2010. doi:10.1016/S1075-6280 (10) 35001-4.
15. Pfizer Citizen Petition. Docket no. 2005P-0452. FDA's decision concerning approvals of generic versions of atorvastatin. 2005.
16. Kim JS, Kim MS, Park HJ, Jin SJ, Lee S, Hwang SJ. Physicochemical properties and oral bioavailability of amorphous atorvastatin hemi-calcium using spray-drying and SAS process. Int J Pharm. 2008;359:211-9.
17. Kim MS, Jin SJ, Kim JS, Park HJ, Song HS, Neubert RH et al. Preparation, characterization and in vivo evaluation of amorphous atorvastatin calcium nanoparticles using supercritical antisolvent (SAS) process. Eur J Pharm Biopharm. 2008;69:454-65.
18. Zhang H, Wang J, Zhang Z, Le Y, Shen Z, Chen J. Micronization of atorvastatin calcium by antisolvent precipitation process. Int J Pharm. 2009;374:106-13.
19. Thomas LC. TA Instruments application notes-use of multiple heating rate DSC and modulated temperature DSC to detect and analyze temperature-time- dependent transitions in materials. 2001.
20. Nogami H, Nagai T, Suzuki A. Studies on powdered preparations. XVII. Dissolution rate of sulfonamides by rotating disk method. Chem Pharm Bull. 1966;14:329-38.
21. *)]-2-(4- difluoro-phenyl) 3-phenyl-4-[(phenylamino) carbonyl]-1H-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin) US Patent 5969156. 1999.
22. Schawe J E K, Strobl GR. Superheating effect during the melting of crystallites of syndiotactic polypropyleene analysed by temperature-modulated differential scanning calorimetry. Polymer. 1998;39:3745-51.
23. Zallen R. The formation of amorphous solids. In: The Physics of amorphous solids. New York: Wiley; 1983. p. 1-22.
24. Buckton G. Wetting, solubility, dissolution and absorption. In: Buckton G, editor. Interfacial phenomena in drug delivery and targeting. Switzerland: Harwood Academic Publishers; 1995. p. 197-206.
25. Prestidge CA, George T. Wettability studies of morphine sulfate powders. Int J Pharm. 2000;198:201-12.
26. Buckton G. Surface characterization: understanding sources of variability in the production and use of pharmaceuticals. J Pharm Pharmacol. 1995;47:265-75.
27. Buckton G. Characterisation of small changes in the physical properties of powders of significance for dry powder inhaler formulations. Adv Drug Delivery Rev. 1997;26:17-27.
28. Newell HE, Buckton G, Butler DA, Thielmann F, Williams DR. The use of inverse gas chromatography to measure the surface energy of crystalline, amorphous, and recently milled lactose. Pharm Res. 2001;18:662-6.